Clarithromycin containing triple therapy Helicobacter pylori eradication compared with levofloxacin containing triple therapy
- Conditions
- Eradication of Helicobacter pylori.Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
- Registration Number
- IRCT2015110224825N1
- Lead Sponsor
- Mazandaran University of medical sciences,Deputy of Research and Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
inclusion criteria: All patients underwent endoscopy with duodenal ulcer or gastric or duodenal or stomach inflammation and Erosion referred to the clinic / office professor interviewed Sari hospital reported that Helicobacter pylori positive and study are older than 18 years
Exclusion criteria: Pregnancy and breastfeeding; H. pylori eradication has already been received; During the last two weeks patients with PPI or H2 RA (histamine 2 receptor antagonist), or within the last 4 weeks have received antibiotics or bismuth; Concomitant use of anticoagulants; corticosteroids or ketoconazole; Patients with a history of stomach surgery; Patients with advanced disease confirmed and severe cardiac; pulmonary;Endocrine; chronic renal failure; chronic liver disease and cancer; alcohol consumption; With a history of peptic ulcer bleeding ulcer complications
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication of Helicobacter pylor. Timepoint: 10 days after treatment,4 Weeks after treatment ppI,Four weeks after discontinuation of medication for respiratory test. Method of measurement: Through the breath test 14 C- UBT.
- Secondary Outcome Measures
Name Time Method Headache?Dizziness?Confusion. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Bitter mouth. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Diarrhea-vomiting. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Skin complications. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Nausea , abdominal pain. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Side effects reported by patients include hypersensitivity reactions. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Constipation Decreased appetite. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Changes in taste. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.